Booz Allen Hamilton to Pay $377.5 Million Fine Over Past Accounting Practices
By Denny Jacob
Booz Allen Hamilton entered a settlement agreement regarding a previously disclosed investigation over its cost accounting and indirect cost charging practices.
The management and technology consulting services provider said Friday that the previously disclosed civil investigation related to certain elements of its practices that took place from 2011 to 2021. The agreement was with the U.S., acting through the Department of Justice and on behalf of the Defense Contract Management Agency.
Booz Allen agreed to pay $377.5 million, which it expects to pay with cash on hand and by drawing on its revolving credit facility, according to a regulatory filing.
The company said it entered the agreement to avoid protracted litigation but added it wasn't an admission of liability.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
July 21, 2023 16:37 ET (20:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track